Orthofix Medical Inc. (NASDAQ:OFIX) Insider Sells $50,790.96 in Stock

Orthofix Medical Inc. (NASDAQ:OFIX) insider Jorge Andres Cedron sold 3,816 shares of Orthofix Medical stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $13.31, for a total transaction of $50,790.96. Following the sale, the insider now owns 42,500 shares of the company’s stock, valued at approximately $565,675. This represents a 8.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Orthofix Medical Stock Performance

Shares of OFIX opened at $13.03 on Monday. The stock has a 50-day simple moving average of $16.25 and a 200-day simple moving average of $17.17. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. Orthofix Medical Inc. has a 1 year low of $12.08 and a 1 year high of $20.73. The stock has a market capitalization of $508.46 million, a PE ratio of -4.16 and a beta of 0.99.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its stake in shares of Orthofix Medical by 421.1% during the first quarter. Assenagon Asset Management S.A. now owns 72,226 shares of the medical device company’s stock worth $1,178,000 after purchasing an additional 58,366 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Orthofix Medical by 1,585.1% in the 1st quarter. GAMMA Investing LLC now owns 22,867 shares of the medical device company’s stock valued at $373,000 after acquiring an additional 21,510 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Orthofix Medical by 14.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,371 shares of the medical device company’s stock worth $1,246,000 after acquiring an additional 8,772 shares in the last quarter. Soleus Capital Management L.P. increased its stake in Orthofix Medical by 13.1% in the fourth quarter. Soleus Capital Management L.P. now owns 686,374 shares of the medical device company’s stock valued at $11,984,000 after purchasing an additional 79,441 shares during the last quarter. Finally, State of Wyoming raised its holdings in Orthofix Medical by 206.8% during the fourth quarter. State of Wyoming now owns 9,432 shares of the medical device company’s stock worth $165,000 after purchasing an additional 6,358 shares in the last quarter. Institutional investors and hedge funds own 89.76% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on OFIX. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $24.00 target price on shares of Orthofix Medical in a research report on Wednesday, February 26th. StockNews.com raised shares of Orthofix Medical from a “hold” rating to a “buy” rating in a research note on Tuesday, February 25th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $22.00 target price on shares of Orthofix Medical in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.